REPORTS

Let’s Pullulate and Expand Your Business

Prostrate Specific Antigen (Psa) Testing Market - Global Professional Analysis and Forecast to 2026

Oct 27, 2019  |  203 PAGES  |  REPORT CODE: CMM225839
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Prostrate Specific Antigen (Psa) Testing market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 9.2% during the forecast period.

This report presents the market size and development trends by detailing the Prostrate Specific Antigen (Psa) Testing market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Prostrate Specific Antigen (Psa) Testing market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Prostrate Specific Antigen (Psa) Testing industry and will help you to build a panoramic view of the industrial development.

Prostrate Specific Antigen (Psa) Testing Market, By Type:

  • Type 1

  • Type 2

  • Type 3

Prostrate Specific Antigen (Psa) Testing Market, By Application:

  • End-User 1

  • End-User 2

  • End-User 3

Some of the leading players are as follows:

  • Bristol - Myers Squibb Company

  • Roche Diagnostics

  • Abbott Laboratories, Inc.

  • GE Helathcare

  • Olympus

  • Pharmacia Delfia

  • UroLogix, Inc.

  • Johnson & Johnson Diagnostics

  • Tosho

  • Beckman Coulter, Inc.

  • Novartis Pharma AG.

  • BioChem Pharma

  • AstraZeneca plc.

  • Bayer AG

  • GlaxoSmithKline, plc.

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Prostrate Specific Antigen (Psa) Testing Market: Technology Type Analysis

  • 4.1 Prostrate Specific Antigen (Psa) Testing Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Prostrate Specific Antigen (Psa) Testing Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Type 1

    • 4.3.2 Type 2

    • 4.3.3 Type 3

5 Prostrate Specific Antigen (Psa) Testing Market: Product Analysis

  • 5.1 Prostrate Specific Antigen (Psa) Testing Product Market Share Analysis, 2018 & 2026

  • 5.2 Prostrate Specific Antigen (Psa) Testing Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Prostrate Specific Antigen (Psa) Testing Market: Application Analysis

  • 6.1 Prostrate Specific Antigen (Psa) Testing Application Market Share Analysis, 2018 & 2026

  • 6.2 Prostrate Specific Antigen (Psa) Testing Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 End-User 1

    • 6.3.2 End-User 1

    • 6.3.3 End-User 3

7 Prostrate Specific Antigen (Psa) Testing Market: Regional Analysis

  • 7.1 Prostrate Specific Antigen (Psa) Testing Regional Market Share Analysis, 2018 & 2026

  • 7.2 Prostrate Specific Antigen (Psa) Testing Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Bristol - Myers Squibb Company

    • 9.1.1 Bristol - Myers Squibb Company Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Roche Diagnostics

    • 9.2.1 Roche Diagnostics Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Abbott Laboratories, Inc.

    • 9.3.1 Abbott Laboratories, Inc. Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 GE Helathcare

    • 9.4.1 GE Helathcare Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Olympus

    • 9.5.1 Olympus Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Pharmacia Delfia

    • 9.6.1 Pharmacia Delfia Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 UroLogix, Inc.

    • 9.7.1 UroLogix, Inc. Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Johnson & Johnson Diagnostics

    • 9.8.1 Johnson & Johnson Diagnostics Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Tosho

    • 9.9.1 Tosho Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Beckman Coulter, Inc.

    • 9.10.1 Beckman Coulter, Inc. Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Novartis Pharma AG.

    • 9.11.1 Novartis Pharma AG. Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 BioChem Pharma

    • 9.12.1 BioChem Pharma Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 AstraZeneca plc.

    • 9.13.1 AstraZeneca plc. Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Bayer AG

    • 9.14.1 Bayer AG Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 GlaxoSmithKline, plc.

    • 9.15.1 GlaxoSmithKline, plc. Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

 

The List of Tables and Figures (Totals 82 Figures and 135 Tables)

  • Figure Type 1 Prostrate Specific Antigen (Psa) Testing market, 2015 - 2026 (USD Million)

  • Figure Type 2 Prostrate Specific Antigen (Psa) Testing market, 2015 - 2026 (USD Million)

  • Figure Type 3 Prostrate Specific Antigen (Psa) Testing market, 2015 - 2026 (USD Million)

  • Figure End-User 1 market, 2015 - 2026 (USD Million)

  • Figure End-User 2 market, 2015 - 2026 (USD Million)

  • Figure End-User 3 market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Prostrate Specific Antigen (Psa) Testing market, by country, 2015 - 2026 (USD Million)

  • Table North America Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table North America Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table North America Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Canada Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Canada Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Europe Prostrate Specific Antigen (Psa) Testing market, by country, 2015 - 2026 (USD Million)

  • Table Europe Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Europe Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Europe Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Germany Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Germany Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table France Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table France Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Italy Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Italy Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Spain Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Spain Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Prostrate Specific Antigen (Psa) Testing market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table China Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table China Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Japan Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Japan Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table India Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table India Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Prostrate Specific Antigen (Psa) Testing market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table MEA Prostrate Specific Antigen (Psa) Testing market, by country, 2015 - 2026 (USD Million)

  • Table MEA Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table MEA Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table MEA Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Prostrate Specific Antigen (Psa) Testing market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Prostrate Specific Antigen (Psa) Testing market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Prostrate Specific Antigen (Psa) Testing market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Bristol - Myers Squibb Company Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Roche Diagnostics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Abbott Laboratories, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GE Helathcare Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Olympus Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pharmacia Delfia Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table UroLogix, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Johnson & Johnson Diagnostics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Tosho Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Beckman Coulter, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis Pharma AG. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table BioChem Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca plc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline, plc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top